Ilia I. Ouspenski

Array ( [id] => 9850014 [patent_doc_number] => 08951740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-10 [patent_title] => 'Genotoxicity as a biomarker for inflammation' [patent_app_type] => utility [patent_app_number] => 13/865798 [patent_app_country] => US [patent_app_date] => 2013-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 35 [patent_no_of_words] => 17378 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13865798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8976049 [patent_doc_number] => 20130209479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 13/860329 [patent_app_country] => US [patent_app_date] => 2013-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11557 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13860329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9134378 [patent_doc_number] => 20130295092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-07 [patent_title] => 'Method for the Treatment of Neurodegenerative Diseases' [patent_app_type] => utility [patent_app_number] => 13/858667 [patent_app_country] => US [patent_app_date] => 2013-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 7190 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13858667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173920 [patent_doc_number] => 20130315905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'B7-H5, A Costimulatory Polypeptide' [patent_app_type] => utility [patent_app_number] => 13/852888 [patent_app_country] => US [patent_app_date] => 2013-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 11448 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13852888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9964796 [patent_doc_number] => 09012408 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-21 [patent_title] => 'Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis' [patent_app_type] => utility [patent_app_number] => 13/851166 [patent_app_country] => US [patent_app_date] => 2013-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 2 [patent_no_of_words] => 26116 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13851166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11486230 [patent_doc_number] => 09592289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Stable IgG4 based binding agent formulations' [patent_app_type] => utility [patent_app_number] => 13/850849 [patent_app_country] => US [patent_app_date] => 2013-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 38 [patent_no_of_words] => 60329 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13850849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11486230 [patent_doc_number] => 09592289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Stable IgG4 based binding agent formulations' [patent_app_type] => utility [patent_app_number] => 13/850849 [patent_app_country] => US [patent_app_date] => 2013-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 38 [patent_no_of_words] => 60329 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13850849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9930909 [patent_doc_number] => 20150079100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-19 [patent_title] => 'METHODS OF TREATMENTS USING CTLA-4 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/386917 [patent_app_country] => US [patent_app_date] => 2013-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 18407 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9719713 [patent_doc_number] => 20140255411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS' [patent_app_type] => utility [patent_app_number] => 13/845420 [patent_app_country] => US [patent_app_date] => 2013-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 128 [patent_figures_cnt] => 128 [patent_no_of_words] => 126492 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13845420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9896067 [patent_doc_number] => 20150051266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN' [patent_app_type] => utility [patent_app_number] => 14/389677 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15445 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14389677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9173928 [patent_doc_number] => 20130315913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'ANTI-LIGHT ANTIBODY THERAPY FOR INFLAMMATORY BOWEL DISEASE' [patent_app_type] => utility [patent_app_number] => 13/840260 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17750 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13840260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10063906 [patent_doc_number] => 09102737 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-11 [patent_title] => 'Human anti-CD27 antibodies, methods and uses' [patent_app_type] => utility [patent_app_number] => 13/835518 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 28326 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13835518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9831896 [patent_doc_number] => 08940710 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-27 [patent_title] => 'Human monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 13/836907 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33229 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13836907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10193015 [patent_doc_number] => 09221911 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-29 [patent_title] => 'Anti-CLTA4, anti-GLUT2 protein for the treatment of type 1 diabetes' [patent_app_type] => utility [patent_app_number] => 13/843123 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 24978 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13843123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11284009 [patent_doc_number] => 09499855 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-22 [patent_title] => 'Compositions, methods, and computer systems related to making and administering modified T cells' [patent_app_type] => utility [patent_app_number] => 13/827960 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 20077 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13827960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9107133 [patent_doc_number] => 20130280265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-24 [patent_title] => 'SYNERGISTIC ANTI-TUMOR EFFICACY USING ALLOANTIGEN COMBINATION IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 13/830462 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13884 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13830462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081021 [patent_doc_number] => 20130266551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN' [patent_app_type] => utility [patent_app_number] => 13/826258 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 27681 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13826258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11480705 [patent_doc_number] => 09587237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'Compositions, methods, and computer systems related to making and administering modified T cells' [patent_app_type] => utility [patent_app_number] => 13/804224 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 20079 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13804224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9093767 [patent_doc_number] => 20130273078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'SYNERGISTIC ANTI-TUMOR EFFICACY USING ALLOANTIGEN COMBINATION IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 13/830543 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13889 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13830543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9124214 [patent_doc_number] => 20130291136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/802172 [patent_app_country] => US [patent_app_date] => 2013-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 41601 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13802172 [rel_patent_id] =>[rel_patent_doc_number] =>)